New research has found that smart watches can be used to detect atrial fibrillation accurately using an electrocardiogram application. Atrial fibrillation is an irregular heart rhythm that may cause blood clots. It also heightens an individual’s risk of heart failure and stroke, among other heart-related complications.
The research, which was conducted earlier this year, discovered that the Apple Watch could be used to diagnose this arrhythmia. For their study, the researchers looked into the accuracy of this device when testing individuals who had abnormal electrocardiograms.
The lead author of the study, Dr. Marc Strick, stated that this technology was widely used, with data showing that roughly 50 million Apple Watches had been sold this year. The researchers used 734 individuals who had been hospitalized as participants in the study. Each patient underwent a 12-lead electrocardiogram, which was followed by an electrocardiogram recording done using the Apple Watch.
The smart device classified the 30-second recordings as atrial fibrillation, no signs of atrial fibrillation or inconclusive readings. Once this was done, an electrophysiologist viewed the smart watch recordings blindly, categorizing them as absence of atrial fibrillation, atrial fibrillation and diagnosis unclear. The researchers then had a different electrophysiologist interpret selected electrocardiogram recordings randomly.
They discovered that the Apple Watch failed to produce an automatic diagnosis in 20% of the incidents, explaining that the possibility of obtaining a false negative was higher in individuals with premature ventricular and atrial contractions, second- or third-degree atrioventricular block, and sinus mode dysfunction. This risk was also higher in individuals with pacemakers as well as in those with other heart-rate abnormalities.
The researchers also reported that the application accurately identified 81% and 78% of individuals without and with atrial fibrillation incidents, respectively. Comparably, both electrophysiologists identified 89% who did not have and 97% of individuals who did have atrial fibrillation incidents. Additionally, the researchers found that the smart watch application was more likely to give a false positive in individuals with premature ventricular contractions.
A cardiologist who has specialized in cardiac implantable electronic devices, Strick added that more healthcare professionals were embracing the technology. He noted that, despite this, the device’s application in clinical practice was limited because of algorithm limitations, lack of organization and reimbursement issues.
The researchers noted in their report that the lack of immediate feedback and the device’s limited battery life could reduce its effectiveness. The study’s findings were reported in the “Canadian Journal of Cardiology.”
As technologies to detect heart disease more easily become available from innovative entities such as HeartBeam Inc. (NASDAQ: BEAT), the cost and availability of the latest ECG equipment is likely to drop significantly.
NOTE TO INVESTORS: The latest news and updates relating to HeartBeam Inc. (NASDAQ: BEAT) are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies…
Researchers at Washington University (WashU) Medicine have conducted a small clinical trial testing a new…
For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in…
About 90% of men that undergo prostate cancer treatment, and almost 50% of men treated…
BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades.…
BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies —…